Gene:
MYC
v-myc myelocytomatosis viral oncogene homolog (avian)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  bHLHe39; c-Myc
PharmGKB Accession Id: PA31353

Details

Cytogenetic Location: chr8 : q24.21 - q24.21
GP mRNA Boundary: chr8 : 128748315 - 128753680
GP Gene Boundary: chr8 : 128738315 - 128756680
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. EGFR Inhibitor Pathway, Pharmacodynamics
    Model non-tissue specific cancer cell displaying genes that may be involved in the treatment using epidermal growth factor receptor specific tyrosine kinase inhibitors or monoclonal antibodies.

External Pathways

Links to non-PharmGKB pathways.

  1. cadmium induces dna synthesis and proliferation in macrophages - (BioCarta via Pathway Interaction Database)
  2. Canonical Wnt signaling pathway - (Pathway Interaction Database NCI-Nature Curated)
  3. Ceramide signaling pathway - (Pathway Interaction Database NCI-Nature Curated)
  4. ctcf: first multivalent nuclear factor - (BioCarta via Pathway Interaction Database)
  5. erk1/erk2 mapk signaling pathway - (BioCarta via Pathway Interaction Database)
  6. FOXM1 transcription factor network - (Pathway Interaction Database NCI-Nature Curated)
  7. il-2 receptor beta chain in t cell activation - (BioCarta via Pathway Interaction Database)
  8. IL2 signaling events mediated by PI3K - (Pathway Interaction Database NCI-Nature Curated)
  9. IL2 signaling events mediated by STAT5 - (Pathway Interaction Database NCI-Nature Curated)
  10. IL2-mediated signaling events - (Pathway Interaction Database NCI-Nature Curated)
  11. IL6-mediated signaling events - (Pathway Interaction Database NCI-Nature Curated)
  12. inhibition of cellular proliferation by gleevec - (BioCarta via Pathway Interaction Database)
  13. mapkinase signaling pathway - (BioCarta via Pathway Interaction Database)
  14. overview of telomerase protein component gene htert transcriptional regulation - (BioCarta via Pathway Interaction Database)
  15. p38 mapk signaling pathway - (BioCarta via Pathway Interaction Database)
  16. PDGFR-beta signaling pathway - (Pathway Interaction Database NCI-Nature Curated)
  17. Presenilin action in Notch and Wnt signaling - (Pathway Interaction Database NCI-Nature Curated)
  18. Regulation of nuclear SMAD2/3 signaling - (Pathway Interaction Database NCI-Nature Curated)
  19. Regulation of Telomerase - (Pathway Interaction Database NCI-Nature Curated)
  20. role of egf receptor transactivation by gpcrs in cardiac hypertrophy - (BioCarta via Pathway Interaction Database)
  21. telomeres telomerase cellular aging and immortality - (BioCarta via Pathway Interaction Database)
  22. tumor suppressor arf inhibits ribosomal biogenesis - (BioCarta via Pathway Interaction Database)
  23. wnt signaling pathway - (BioCarta via Pathway Interaction Database)

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
MAPK1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
MAPK3
No related diseases are available

Publications related to MYC: 14

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nature genetics. 2014. Knoechel Birgit, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Statin induced changes in gene expression in EBV-transformed and native B-cells. Human molecular genetics. 2013. Bolotin Eugene, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene. 2013. Nair R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer. PLoS biology. 2012. Kalyuga Maria, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy. The pharmacogenomics journal. 2010. Kim H K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clinical pharmacology and therapeutics. 2010. Stegmeier F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic identification of c-Myc/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines. Molecules (Basel, Switzerland). 2010. Sertel Serkan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leukemia research. 2010. Valdez Benigno C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. The Journal of biological chemistry. 2008. Liu Zhengyu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. American journal of human genetics. 2007. Huang R Stephanie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nature genetics. 2007. Gudmundsson Julius, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nature genetics. 2007. Yeager Meredith, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Multiple regions within 8q24 independently affect risk for prostate cancer. Nature genetics. 2007. Haiman Christopher A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer cell. 2002. Yeoh Eng-Juh, et al. PubMed

LinkOuts

Entrez Gene:
4609
OMIM:
113970
190080
UCSC Genome Browser:
NM_002467
RefSeq RNA:
NM_002467
RefSeq Protein:
NP_002458
RefSeq DNA:
AC_000051
AC_000140
NC_000008
NG_007161
NT_008046
NW_001839136
NW_923984
UniProtKB:
MYC_HUMAN (P01106)
Ensembl:
ENSG00000136997
GenAtlas:
MYC
GeneCard:
MYC
MutDB:
MYC
ALFRED:
LO235396C
HuGE:
MYC
Comparative Toxicogenomics Database:
4609
ModBase:
P01106
HumanCyc Gene:
HS06259
HGNC:
7553

Common Searches